Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Bextra Label Changes Under Discussion After Hypersensitivity Reactions

  • News

Executive Summary

Pfizer and Pharmacia are in discussions with FDA regarding safety-related label changes for Bextra, Pfizer said during its third quarter earnings call Oct. 16

You may also be interested in...



Pfizer/Pharmacia Bextra Adds Hypersensitivity And Skin Reaction Warnings

Pfizer and Pharmacia will be alerting physicians to a new warning statement in Bextra (valdecoxib) labeling about skin and hypersensitivity reactions to the COX-2 inhibitor

Pfizer/Pharmacia Bextra Adds Hypersensitivity And Skin Reaction Warnings

Pfizer and Pharmacia will be alerting physicians to a new warning statement in Bextra (valdecoxib) labeling about skin and hypersensitivity reactions to the COX-2 inhibitor

Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events

Merck will conduct a 6,000-patient study of Arcoxia focusing on patient discontinuations due to gastrointestinal adverse events

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS040639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By